Search

Displaying results 4321 - 4330 of 10000 in total
  1. Drug

    AT9283

    go.drugbank.com/drugs/DB05169
    Investigational

    AT9283 is an aurora Kinase inhibitor developed by Astex Therapeutics for the treatment of cancer. … It was discovered and developed internally using Astex’s fragment-based drug discovery platform, Pyramid.

  2. Drug

    Iobenguane sulfate I-123

    go.drugbank.com/drugs/DB09546
    Approved

    Iobenguane sulfate I-123 is a radiopharmaceutical used in gamma-scintigraphy of adrenergically inervated tissues [FDA Label].

    Synonyms: Iobenguane sulfate I 123, Iobenguane sulfate I-123Products: i 123 MIBG meta iodobenzylguanidine
  3. Drug

    LGD-1550

    go.drugbank.com/drugs/DB05785
    Experimental

    LGD-1550 is an orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.

  4. Drug

    Guanoxan

    go.drugbank.com/drugs/DB13211
    Approved

    Guanoxan is an antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage. … Guanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity.

  5. Drug

    Prednisolone

    go.drugbank.com/drugs/DB00860
    ApprovedInvestigationalVet approved

    Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.

    International brands: Ak-PredCategories: Corticosteroids, Weak (Group I), Corticosteroid Hormone Receptor Agonists
  6. Drug

    Trilaciclib

    go.drugbank.com/drugs/DB15442
    ApprovedInvestigational

    [L31828] CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis and chemotherapy.[A229323] Trilaciclib was first described in the literature in 2016. … Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing

    Categories: MATE 2-K Inhibitors
  7. Drug

    DG051

    go.drugbank.com/drugs/DB05177
    Experimental

    DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and a potent promoter of inflammation. … DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack.

  8. Drug

    AMG-222

    go.drugbank.com/drugs/DB06011
    Experimental

    Categories: DPP-IV Inhibitors
  9. Drug

    Piperacetazine

    go.drugbank.com/drugs/DB06808
    ApprovedVet approvedWithdrawn

    Piperacetazine was an antipsychotic.

  10. Drug

    Ethambutol

    go.drugbank.com/drugs/DB00330
    ApprovedInvestigational

    [L31743] Ethambutol was first described in the literature in 1961.[A229048] It was developed out of a need for therapies active against isoniazid resistant strains of _Mycobacterium tuberculosis_. … Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and [pyrazinamide] in the treatment of pulmonary tuberculosis.